Intervention

DMARDs

ClinicalTrials.gov intervention label

Clinical trials14

Recruiting0

Common conditions8

Lead sponsors shown10

Clinical trials

14 shown

Cortisol Circadian Rhythm in Patients With RANCT05671627 · 2022-02-02

PANLAR's Latin American Registry of Rheumatic Patients Treated With Jak InhibitorsNCT04821206 · 2021-03-01

Immunosuppressant Combined With Pirfenidone in CTD-ILDNCT04928586 · 2019-08-16

Rheumatoid Arthritis Memory B Cells and AbataceptNCT03652961 · 2019-06-02

Optimal MTX Dose With Folic Acid Randomized Case-control TrialNCT04066803 · 2018-08-01

Human Umbilical Cord-Mesenchymal Stem Cells for Rheumatoid ArthritisNCT02643823 · 2016-01-01

A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic AgentNCT02046603 · 2014-03-04

A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) ParticipantsNCT01941940 · 2013-09-05

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With DMARDs Versus DMARDs Alone in Patients With Rheumatoid ArthritisNCT01787149 · 2013-09-01

A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488NCT01715831 · 2013-01-15

RHYTHM (Formerly Escape II Myocardium)NCT01548768 · 2011-10-10

To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid ArthritisNCT01256736 · 2010-03-01

A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDsNCT00996606 · 2009-10-01

Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid ArthritisNCT01211834 · 2009-10-01

Common conditions

Rheumatoid Arthritis10 Arthritis, Rheumatoid2 Arthritis, Psoriatic1 Combination With DMARDs1 Connective Tissue Diseases1 Interstitial Lung Disease1 Pirfenidone1 Spondyloarthritis1

Leading sponsors

Hoffmann-La Roche4 JW Pharmaceutical2 Columbia University1 Liga Panamericana de Asociaciones de Reumatologia (PANLAR)1 Mycenax Biotech Inc.1 National and Kapodistrian University of Athens1 NYU Langone Health1 Qilu Hospital of Shandong University1 Shenzhen Hornetcorn Bio-technology Company, LTD1 Sun Yat-sen University1

Trial status mix

COMPLETED8

UNKNOWN6

Phase mix

PHASE36

PHASE45

PHASE11

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.